Kyverna Therapeutics, Inc. (KYTX) News
Track canonical SquawkNews coverage tagged to KYTX, Kyverna Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Kyverna Therapeutics Q2 EPS $(0.63) Beats $(0.68) Estimate
Kyverna Therapeutics (NASDAQ: KYTX ) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.68) by 7.35 percent. This is a 35.05 percent increase over losses of $(0.97) per share
EARNINGS | Aug 11, 2026, 08:18 PM UTC
L
KYTX - Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
KYTX - Kyverna Therapeutics Reports Pipeline Progress and Second Quarter 2026 Financial Results
EARNINGS | Aug 11, 2026, 08:02 PM UTC
L
KYTX Kyverna Therapeutics and elevatebio enter into commercial manufacturing and supply agreement for miv-cel Kyverna Therapeutics - agreeme
KYTX Kyverna Therapeutics and elevatebio enter into commercial manufacturing and supply agreement for miv-cel Kyverna Therapeutics - agreement provides scalable miv-cel supply for potential Sps and gmg launches - On trac
EQUITY | Jul 27, 2026, 12:01 PM UTC
L
KYTX Appoints Chief Legal Officer
Kyverna Therapeutics appoints Ritesh Srivastava as Chief Legal and Compliance Officer to support commercial-stage transition
EQUITY | Jun 22, 2026, 12:01 PM UTC